Suprachoroidal silicone tube shunt implantation successful in glaucoma surgery

Article

Suprachoroidal silicone tube drainage of aqueous humour effectively reduces intraocular pressure (IOP) in glaucoma patients

Suprachoroidal silicone tube drainage of aqueous humour effectively reduces intraocular pressure (IOP) in glaucoma patients, according to a study published in the Journal of Glaucoma.

Dr Metin Unal et al., Ulucanlar Eye Education and Research Hospital, Ankara, Turkey, studied 24 glaucomatous eyes that were unresponsive to medical treatment, including 7 eyes that underwent earlier trabeculectomy. A limbus-based scleral flap and a 1.5 mm deep sclerotomy adjacent to the flap opening was created. The posterior end of the tube was placed in the suprachoroidal space and the anterior end was put into the anterior chamber. IOP and best corrected visual acuities (BCVA) were measured preoperatively and postoperatively on the first day, then the first week and in the first, third, sixth, twelfth and eighteen months.

The tube was considered as a failure if postoperative IOP was greater than 21 mm Hg, lower than 5 mm Hg or if additional surgery was required. Eyes that did not require supplemental medical therapy were identified as a complete success. Eyes that had an IOP within the range, regardless of whether they had additional medical therapy, were considered as a qualified success.

After a mean postoperative follow-up period of 4.4±23.7 weeks, the mean IOP had significantly reduced compared to preoperative data. Results demonstrated a complete success rate of 95.8%±4.1 in the first week, 79.2%±8.3 in the first and the third months, and 63.3%±12.0 for the sixth and twelfth month. Qualified success rates were 95.8%±4.1 in the first week, 87.5%±6.8 in the first, third, sixth, twelfth months. Of the eyes studied, 7 were classed as failures and early hypotony was identified in 6 eyes. Intracameral bleeding was found in 2 patients and 3 patients experienced a fibrin reaction in the anterior chamber. There was no record of infection, choroidal or retinal detachment. The suprachoroidal silicone tube shunt implantation is a safe and effective treatment for glaucoma patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.